Shingles Vaccine Shingrix Shows Promise in Reducing Dementia in Seniors

A recent study by Brown University suggests that the latest shingles vaccine, Shingrix, could significantly impact dementia rates among nursing home residents. The vaccine, developed by GlaxoSmithKline in 2017, is linked to a 24% decrease in dementia diagnoses in older adults who received it at or soon after admission, tracked over four years.

The research, financially backed by GlaxoSmithKline but independently designed and analyzed, scrutinized health and Medicare records of over 500,000 individuals aged 66 and above admitted to nursing facilities from 2017 to 2022. Findings indicated that 18.8% of vaccinated residents developed dementia, compared to 24.6% of those unvaccinated, suggesting the potential to prevent one in every 17 dementia cases.

Kaley Hayes, an author of the study and assistant professor at Brown University's School of Public Health, noted that this research differs from prior studies focusing on older vaccine variants. Instead, it targeted an at-risk, older demographic newly admitted to skilled nursing facilities, accentuating the benefits of vaccinations during critical healthcare transitions.

While the results are promising, the study could not definitively attribute dementia prevention directly to the vaccine, with the vaccinated group being slightly younger and probably healthier. Further clinical trials are necessary to substantiate these results. Hayes emphasized the emerging connection between physical health interventions and cognitive health, advocating for targeted vaccine assessments and strategic planning in nursing homes to protect populations vulnerable to both shingles and dementia.